Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty‐eight–week randomized, double‐blind trial

Arthritis & Rheumatism

Volumn 34, Issue 8, 1991, Pages 961-972

  Jeurissen, Maurice E C ^a   Th Boerbooms, Agnes M ^a   Van De Putte, Levinus B A ^a   Doesburg, Wim H ^b   Mulder, Jan ^b   Rasker, Johannes J ^c   Kruijsen, Marijn W M ^c   Haverman, Joost F ^c   Van Beusekom, Henk J ^d   Muller, Wim Hissink ^d   Franssen, Marcel J A M ^e   De Rooy, Dirk‐Jan R A M ^e  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c Medisch Spectrum Enschede ^*  (Netherlands)

^d ST ELISABETH HOSPITAL   (Netherlands)

^e St Maartens Hospital   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AURANOFIN; AUROTHIOGLUCOSE; AZATHIOPRINE; GOLD; HYDROXYCHLOROQUINE; METHOTREXATE; PENICILLAMINE;

ADULT; AGED; ARTICLE; DRUG THERAPY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; AZATHIOPRINE; COMPARATIVE STUDY; DOUBLE-BLIND METHOD; FEMALE; HUMAN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; METHOTREXATE; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T; TIME FACTORS;

EID: 0025912605     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780340805     Document Type: Article

References (44)

1. Methotrexate in rheumatoid arthritis: feedback on American College of Physicians guidelines
2. Remodeling the pyramid: a concept whose time has come
3. Remodeling the pyramid: a concept whose time has not come
4. Methotrexate and rheumatoid arthritis
5. Methotrexate in refractory rheumatoid arthritis
6. Comparison of azathioprine, cyclophosphamide and gold in the treatment of rheumatoid arthritis
7. Azathioprine in early rheumatoid arthritis: comparison with gold and chloroquine
8. Comparison of azathioprine and cyclophosphamide in the treatment of rheumatoid arthritis (abstract)
9. Azathioprine and penicillamine in treatment of rheumatoid arthritis: a controlled trial
10. Azathioprine versus D‐penicillamine in rheumatoid arthritis patients who have been treated unsuccessfully with gold
11. Double blind trial of levamisole, penicillamine, azathioprine in rheumatoid arthritis
12. A randomized controlled trial of parenteral methotrexate compared with sodium aurothiomalate
13. Gold sodium thiomalate compared to low dose methotrexate in the treatment of rheumatoid arthritis: a randomized double blind 26 week trial
14. A controlled two center trial of parenteral methotrexate for refractory rheumatoid arthritis
15. Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunological effects in a randomized double‐blind study
16. Efficacy of low dose methotrexate in rheumatoid arthritis
17. Comparison of low dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis
18. Long‐term prospective trial of low‐dose methotrexate in rheumatoid arthritis
19. A long‐term prospective study of the use of methotrexate in rheumatoid arthritis: update after a mean of fifty‐three months
20. Low dose methotrexate of rheumatoid arthritis: long‐term observations
21. Prospective long‐term follow‐up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression
22. Low‐dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: a twenty‐four–week controlled clinical trial
23. A double‐blind randomized controlled trial of azathioprine and methotrexate in the treatment of rheumatoid arthritis (abstract)
24. 1958 revision of diagnostic criteria for rheumatoid arthritis
25. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
26. Therapeutic criteria in rheumatoid arthritis
27. Prediction of creatinine clearance from serum creatinine
28. Clinical studies with an articular index for assessment of joint tenderness in patients with rheumatoid arthritis
29. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a “diseáse activity score
30. Validity of disease activity variables in rheumatoid arthritis
31. Azathioprine induced fever, chills, rash and hepatotoxicity in rheumatoid arthritis
32. Pancytopenia related to azathioprine in rheumatoid arthritis
33. Eruption of nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis
34. Azathioprine in rheumatoid arthritis: a double blind, cross‐over study
35. Azathioprine in rheumatoid arthritis: double blind study of full versus half doses versus placebo
36. Azathioprine in rheumatoid arthritis: a double blind study comparing full dose to half dose
37. Methotrexate in rheumatoid arthritis: toxic effects as the major factor in limiting long‐term treatment
38. Toxicity of low dose methotrexate in rheumatoid arthritis
39. Toxicity to methotrexate in rheumatoid arthritis
40. Disease modifying drugs for progression of rheumatoid arthritis
41. Rheumatoid arthritis: treatment with azathioprine (Imuran®). Clinical side effects and laboratory abnormalities
42. Toxic effects of azathioprine in rheumatoid arthritis: a national post‐marketing prospective
43. Azathioprine hypersensitivity: case report and review of the literature